Amur Minerals Corporation Exercise of Warrants and Issue of Equity (3644B)

TIDMAMC

RNS Number : 3644B

Amur Minerals Corporation

11 February 2022

AMUR MINERALS CORPORATION

(AIM: AMC)

Exercise of Warrants and Issue of Equity

Amur Minerals Corporation ("Amur" or the "Company"), the nickel-copper sulphide mineral exploration and resource development company focused on the far east of Russia, announces that, pursuant to the fund raising entered into with Axis Capital Marketing, LTD ("Investor") on 4 November 2019 and the subsequently announced issuance of warrants on 20 February 2020 for the fund raising consideration, the Investor has elected to convert 5,000,000 warrants ("Warrants") at the warrant exercise price of 2.12 pence per share providing the Company GBP106,000. The Investor holds no more warrants.

Application has been made to the London Stock Exchange plc for 5,000,000 new Ordinary Shares to be admitted to trading on the AIM market with admission expected to occur on or around 16 February 2022. The new Ordinary Shares rank pari passu in all respects with the existing Ordinary Shares including the right to receive any dividend or other distribution thereafter declared, made or paid. There are no Ordinary Shares held in treasury. Therefore, the total number of voting rights in the Company, following the issue of 5,000,000 new Ordinary Shares is 1,392,872,315.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014, which was incorporated into UK law by the European Union (Withdrawal) Act 2018, until the release of this announcement.

 
 Company            Nomad and Broker                Public Relations 
  Amur Minerals      S.P. Angel Corporate Finance    Blytheweigh 
  Corp.              LLP 
 Robin Young CEO    Richard Morrison                Megan Ray 
                     Andrew Cowl                     Tim Blythe 
 +44 (0) 7981 126                                   +44 (0) 20 7138 
  818               +44 (0) 20 3470 0470             3203

For additional information on the Company, visit the Company's website, www.amurminerals.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEGPUWUPUPPPGU

(END) Dow Jones Newswires

February 11, 2022 01:59 ET (06:59 GMT)

Crism Therapeutics (AQSE:AMC.GB)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024